Several other research firms also recently weighed in on ILMN. Wolfe Research set a $380.00 target price on Illumina and gave the company a buy rating in a research report on Friday, October 25th. Argus boosted their target price on Illumina from $300.00 to $340.00 and gave the company a buy rating in a research report on Wednesday, September 25th. Piper Jaffray Companies cut their target price on Illumina from $348.00 to $341.00 and set an overweight rating on the stock in a research report on Friday, October 25th. Stifel Nicolaus initiated coverage on Illumina in a research report on Thursday, November 14th. They set a buy rating and a $345.00 target price on the stock. Finally, Guggenheim initiated coverage on Illumina in a report on Friday, October 25th. They set a buy rating and a $350.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Illumina presently has a consensus rating of Buy and an average target price of $333.50.
NASDAQ:ILMN traded up $0.39 during trading hours on Wednesday, reaching $320.97. The stock had a trading volume of 435,331 shares, compared to its average volume of 690,435. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.15 and a current ratio of 6.82. Illumina has a 52 week low of $263.30 and a 52 week high of $380.76. The company has a 50 day moving average price of $309.25 and a two-hundred day moving average price of $310.76. The stock has a market capitalization of $48.01 billion, a PE ratio of 56.11, a PEG ratio of 2.41 and a beta of 1.06.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, October 24th. The life sciences company reported $1.93 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.53. The business had revenue of $907.00 million for the quarter, compared to the consensus estimate of $872.65 million. Illumina had a return on equity of 22.05% and a net margin of 28.14%. The company’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.52 EPS. Equities research analysts predict that Illumina will post 6.45 EPS for the current year.
In related news, SVP Oene Mark Van sold 625 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $304.84, for a total transaction of $190,525.00. Following the completion of the transaction, the senior vice president now owns 14,209 shares in the company, valued at approximately $4,331,471.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Charles Dadswell sold 655 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $320.33, for a total value of $209,816.15. Following the transaction, the senior vice president now owns 11,803 shares of the company’s stock, valued at approximately $3,780,854.99. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,520 shares of company stock valued at $5,038,676. 0.38% of the stock is owned by company insiders.
Several hedge funds have recently modified their holdings of ILMN. Next Capital Management LLC purchased a new stake in shares of Illumina in the 2nd quarter worth $25,000. Massey Quick Simon & CO. LLC lifted its holdings in shares of Illumina by 3,100.0% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 96 shares of the life sciences company’s stock worth $29,000 after buying an additional 93 shares during the period. North Star Investment Management Corp. purchased a new stake in shares of Illumina in the 3rd quarter worth $31,000. Trust Co. of Vermont lifted its holdings in shares of Illumina by 296.8% in the 3rd quarter. Trust Co. of Vermont now owns 123 shares of the life sciences company’s stock worth $37,000 after buying an additional 92 shares during the period. Finally, Winslow Evans & Crocker Inc. lifted its holdings in shares of Illumina by 90.9% in the 3rd quarter. Winslow Evans & Crocker Inc. now owns 126 shares of the life sciences company’s stock worth $40,000 after buying an additional 60 shares during the period. Institutional investors and hedge funds own 91.76% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.